𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Randomized double-blind placebo-controlled trial of early octreotide in patients with postoperative enterocutaneous fistula

✍ Scribed by J. J. Sancho; J. Di Costanzo; P. Nubiola; A. Larrad; A. Beguiristain; F. Roqueta; G. Franch; A. Oliva; J. M. Gubern; Professor A. Sitges-Serra

Publisher
John Wiley and Sons
Year
1995
Tongue
English
Weight
454 KB
Volume
82
Category
Article
ISSN
0007-1323

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Efficacy of methotrexate treatment in pa
Efficacy of methotrexate treatment in patients with probable rheumatoid arthritis: A double-blind, randomized, placebo-controlled trial
✍ Henrike van Dongen; Jill van Aken; Leroy R. Lard; Karen Visser; H. Karel Ronday; πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 124 KB πŸ‘ 2 views

## Abstract ## Objective To determine whether patients with undifferentiated arthritis (UA; inflammatory, nontraumatic arthritis that cannot be diagnosed using current classification criteria) benefit from treatment with methotrexate (MTX). ## Methods The PRObable rheumatoid arthritis: Methotrex

Rituximab in patients with primary progr
Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double-blind placebo-controlled multicenter trial
✍ Kathleen Hawker; Paul O'Connor; Mark S. Freedman; Peter A. Calabresi; Jack Antel πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 English βš– 158 KB πŸ‘ 2 views

## Abstract ## Objective Rituximab, a monoclonal antibody selectively depleting CD20+ B cells, has demonstrated efficacy in reducing disease activity in relapsing‐remitting multiple sclerosis (MS). We evaluated rituximab in adults with primary progressive MS (PPMS) through 96 weeks and safety thro